DealShare’s Unicorn Dream Fades as Truemeds Nears Takeover Deal
What Happened
E-commerce startup DealShare, once valued at $1.7 billion, is reportedly in advanced talks to be acquired by online pharmacy Truemeds in a share-swap transaction worth a little over $90 million. The proposed deal would value DealShare at only slightly above its cash balance, marking a dramatic drop from its peak valuation.
Key Takeaways
The potential acquisition underscores the sharp valuation reset facing several once high-flying startups. If completed, the deal would represent a steep decline for DealShare, which achieved unicorn status in 2022 but has since struggled with falling revenue, restructuring, and leadership exits.